生物可利用的黄素配方对阿尔茨海默氏症病理学的影响:神经炎症的潜在风险
Shaun Cade1, Clive Prestidge2, Xin-Fu Zhou1
1Health and Biomedical Innovation, Clinical and Health Sciences University of South Australia Adelaide South Australia Australia.
Ibrain
|December 18, 2024
概括
在阿尔茨海默病 (AD) 的小鼠模型中,生物可用的黄素没有减少粉样蛋白斑块或改变疾病进展. 然而,它可能会增加神经炎症,这表明更高剂量的潜在风险.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 是一种导致痴呆的神经退行性疾病,其特征是脑蛋白沉积.
- 复杂的神经元和质相互作用可能会在阿尔茨海默病的认知衰退之前.
- 来自黄的黄素通过减轻小鼠模型的神经病理学来治疗AD有希望,但其临床使用因口服生物可用性差而受到限制.
研究的目的:
- 在小鼠模型中评估生物可用的黄素配方对阿尔茨海默病 (AD) 神经病理学的影响.
- 为了确定黄素口服增强的生物可用性是否可以克服AD治疗的配方限制.
主要方法:
- 一种生物可利用的黄素配方通过饮用水给了AD小鼠模型.
- 进行了神经病理学评估,以分析粉样斑块负担和神经炎症标志物.
- 测量了质纤维酸性蛋白质 (GFAP) 的蛋白质水平,以评估星球细胞的反应性.
主要成果:
- 生物可用的黄素配方没有改变转基因小鼠模型中的粉样质斑块的大小或数量.
- 调节粉样β生产的机制保持不变,这表明对AD进展没有重大影响.
- 虽然反应性星球细胞数量没有受到影响,但整体质纤维酸蛋白 (GFAP) 水平增加,这表明神经炎症的潜在恶化.
结论:
- 经过测试的生物可用黄素配方未能改变小鼠关键阿尔茨海默病 (AD) 神经病理.
- 增加的GFAP水平表明,这种黄素配方的较高剂量可能会加剧神经炎症.
- 需要进一步的研究来探索黄素在阿尔茨海默病中的治疗潜力和安全性,考虑到剂量和配方对神经炎症的影响.
相关概念视频
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95


